About: Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn’s Disease Populations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn’s Disease Populations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn’s Disease Populations
Creator	Cavadino, Alana Ellett, Stephanie Ferguson, Lynnette Laing, Bobbi
source	Medline; PMC
abstract	Two trials separately measured the bioavailability and impact on inflammation of a supplement taken daily containing 510 mg Docosahexaenoic acid (DHA), 344 mg Eicosapentaenoic acid (EPA), and 1000 IU of vitamin D (25-hydroxyvitamin D; 25(OH)D), for healthy and Crohn’s disease (CD) populations. Both trials were double blinded, randomized, placebo-controlled with cross-over. Participants were randomly allocated to groups A (placebo then supplement) or B (supplement then placebo). Both included a washout. Fatty acid (N-3 PUFAs) and vitamin D serum levels, plasma C-reactive protein (CRP), and stool calprotectin were measured before and after each treatment period. Outcome measures were analyzed using generalized linear mixed models, including terms for treatment, period, and a treatment-by-period interaction. The supplement significantly increased serum levels in healthy and CD groups for EPA (p < 0.001 and p < 0.001, respectively), Docosapentaenoic acid (p < 0.001 and 0.005), DHA (p < 0.001 and 0.006), the omega-3 index (p < 0.001 and 0.001), and (vitamin D (p < 0.001 and 0.027). CRP and calprotectin measures showed no evidence of a treatment effect on inflammation; however, model estimation was imprecise for both outcomes, hence further research is required to elucidate potential inflammation effects. The nutrient supplement increased serum levels of key N-3 PUFAs and vitamin D in both populations, showing the preparation was readily bioavailable.
has issue date	2020-04-18(xsd:dateTime)
bibo:doi	10.3390/nu12041139
bibo:pmid	32325778
has license	cc-by
sha1sum (hex)	5d6f40989b9891c3844ad89d06a1a5212d2f3c01
schema:url	https://doi.org/10.3390/nu12041139
resource representing a document's title	Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn’s Disease Populations
has PubMed Central identifier	PMC7230517
has PubMed identifier	32325778
schema:publication	Nutrients
resource representing a document's body	covid:5d6f40989b9891c3844ad89d06a1a5212d2f3c01#body_text
is schema:about of	named entity 'model' named entity 'anti-inflammatory' named entity 'populations' named entity 'nutrient' named entity 'calprotectin' named entity 'vitamin D' named entity 'Levels' named entity 'Randomized' named entity 'vitamin D' named entity 'inflammation' named entity 'daily' named entity 'measures' named entity 'placebo-controlled' named entity 'terms' named entity 'plasma' named entity 'CRP' named entity 'measure' named entity 'erythrocyte' named entity '25(OH)D' named entity 'Maresins' named entity 'erythrocyte' named entity 'bioavailability' named entity 'calprotectin' named entity 'erythrocyte' named entity 'Resolvins' named entity 'double blinded' named entity 'plasma' named entity 'omega-3' named entity 'C-reactive protein' named entity 'pro-resolving' named entity 'Double-Blinded' named entity 'Vitamin' named entity 'Serum Levels' named entity 'nmol/L' named entity '0.01' named entity 'ng/mL' named entity 'nutrient' named entity '0.01' named entity 'vitamin' named entity 'fish oil supplement' named entity 'inflammatory conditions' named entity 'nmol/L' named entity 'parietal bone' named entity 'standard deviation' named entity 'vitamin' named entity 'Inclusion and exclusion criteria' named entity 'EPA' named entity 'dietary supplements' named entity 'fatty acids' named entity 'C12:0' named entity 'fish-oil' named entity 'nmol/L' named entity 'prebiotics' named entity 'serum' named entity 'omega-3' named entity 'statistical power' named entity 'red blood cells' named entity 'EPA' named entity 'p-values' named entity 'fatty acid' named entity 'fatty acid' named entity 'nutrition' named entity 'blood thinning' named entity 'Metabolites' named entity 'dietary supplements' named entity 'long chain' named entity 'omega-3' named entity 'small numbers' named entity 'ratio scale' named entity 'peanut oil' named entity 'flax seed oil' named entity 'wild type' named entity '12 weeks' named entity 'EPA' named entity '0.01' named entity 'vitamin D levels' named entity 'skin cancers' named entity 'vitamin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software